iA Global Asset Management Inc. Raises Position in Zimmer Biomet Holdings, Inc. $ZBH

iA Global Asset Management Inc. raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 54.5% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,950 shares of the medical equipment provider’s stock after buying an additional 6,683 shares during the period. iA Global Asset Management Inc.’s holdings in Zimmer Biomet were worth $1,728,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ZBH. Accent Capital Management LLC purchased a new stake in shares of Zimmer Biomet during the 1st quarter worth $35,000. Cullen Frost Bankers Inc. increased its stake in Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 305 shares during the period. Hilltop National Bank acquired a new position in Zimmer Biomet in the second quarter valued at $42,000. Zions Bancorporation National Association UT acquired a new position in Zimmer Biomet in the first quarter valued at $48,000. Finally, Brooklyn Investment Group increased its stake in shares of Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the firm’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $99.86 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The company has a market cap of $19.78 billion, a P/E ratio of 24.30, a P/E/G ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72. The firm’s 50 day moving average is $101.30 and its two-hundred day moving average is $97.64.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ZBH shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Evercore ISI lowered their price target on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 7th. UBS Group increased their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research report on Friday, August 8th. Finally, Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $111.94.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.